POLA1 and diffuse large B-cell lymphoma: Within cycle 1, exposure of pola in patients with treatment-naïve DLBCL receiving pola + R-CHP showed a geometric mean ratio (GMR) for AUC of 0.711 (90% CI 0.616–0.820) for acMMAE and 1.43 (90% CI 1.15–1.78) for unconjugated MMAE when compared with R/R FL patients receiving pola with rituximab (in the absence of CHP); this is likely reflective of cross-study variations and within the variability of each analyte (~ 30% for acMMAE, and ~ 60% for unconjugated MMAE) (Table 2).